Analysts expect Chemomab Therapeutics Ltd. to report revenue of 0.00 for Q4 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q3 24, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | - | - | - | - | - | - | - | - | |||||||||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Chemomab Therapeutics Ltd. to report earnings per share of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00, a 100.0% beat against the -0.15 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.04 | -0.03 | -0.03 | -0.02 | -0.02 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | 0.00 | -0.14 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.01 | -0.01 | -0.02 | ||||||||||
| Low Estimate | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | 0.00 | -0.16 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.01 | -0.01 | -0.02 | ||||||||||
| Consensus Estimate | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | 0.00 | -0.15 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.01 | -0.01 | -0.02 |